Dr. Devyn Smith

Dr. Devyn Smith brings over 20 years of experience in cell and gene therapy development and platform expertise. He joined Arbor Biotechnologies as Chief Executive Officer on April 27, 2021, after serving as Chief Operating Officer (COO) of Sigilon Therapeutics. Prior to Sigilon, Dr. Smith worked in a variety of roles at Pfizer Inc., including as COO of the UK-based Neusentis Unit, which focused on discovering and developing cell therapies. He received his Ph.D. in Genetics from Harvard Medical School and is an inventor on multiple patents, with numerous publications in leading scientific journals. Dr. Smith also serves as a board member and officer for the Alliance for Regenerative Medicine, the cell and gene therapy industry group.